The SHIELD-Utah study compared Novavax’s vaccine to the Pfizer/BioNTech mRNA 2024-2025 vaccine
Category: News
More than 37 million adults in the US are affected by migraine
European Commission grants authorisation for Eisai and Biogen therapy
New real-world data reinforce treatment benefit
Long-term survival projections suggest improved outcomes for patients
Studies show improved bone mineral density and healthcare cost reductions
Major update aims to accelerate research and strengthen patient safety
Birmingham researchers to make MGUS monitoring more efficient
Johnson & Johnson’s Balversa was found to extend the lives of urothelial cancer patients with a genetic alteration
The model could lead to more targeted treatments for the disease